From Bloomberg News | A federal jury has ordered Abbott Laboratories to pay drug giant GlaxoSmithKline $3.5 million in damages in an antitrust lawsuit claiming Abbott sought to stifle competition over HIV drugs when it quadrupled the price of its AIDS medicine Norvir in 2003.
Inside these posts: HIV
Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
Glaxo-Abbott case handed to the jury
A jury began deliberating Friday morning on whether Abbott Laboratories should pay GlaxoSmithKline hundreds of millions of dollars over allegations of unfair HIV drug pricing. Get the full story »
Glaxo lawyer: Abbott used HIV drug as weapon
Abbott Laboratories improperly hiked the price of one drug to help it preserve sales growth of one of its other HIV blockbusters, an attorney for GlaxoSmithKline told a jury. Get the full story »
Abbott settles HIV pricing claims with pharmacies
Abbott Laboratories has agreed to settle a lawsuit brought by CVS Caremark Corp., Rite Aid Corp. and other retailers who accused it of unfairly boosting the price of HIV drugs, a company spokeswoman said. Get the full story »
U.S. warns against Abbott drug in premature babies
U.S. health officials cautioned against the use of Abbott Laboratories’ HIV drug Kaletra in premature babies because they could be at greater risk for serious and possibly fatal side effects.
In a warning issued on Tuesday, the Food and Drug Administration said oral solutions of the drug given to premature babies could raise the risk of serious heart, kidney, or breathing trouble. Get the full story »
Glaxo: Abbott has illegal monopoly in AIDS drugs
From Bloomberg News | GlaxoSmithKline Plc lawyers, in a trial seeking at least $1.5 billion in damages, told jurors that Abbott Laboratories had an illegal monopoly over HIV drugs. Get the full story>>
India rejects Abbott patent of Kaletra AIDS drug
Abbott Laboratories was refused copyright protection on its AIDS drug Kaletra by India’s patent office, allowing Cipla Ltd. and other generic-drug companies to continue selling copies. Get the full story »
Qiagen, Abbott sign contract over HIV, HPV tests
Qiagen NV said Tuesday it will receive kits for a molecular test for HIV-1 in a deal with Abbott Laboratories. Financial details of the deal were not disclosed.
U.N. offers simpler, more effective AIDS treatment
Ten million AIDS deaths could be averted by 2025 and a million new HIV infections prevented every year if countries took a fresh look at how to meet targets for treating the disease, the United Nations AIDS program said Tuesday.
The UNAIDS Outlook report called for a simpler approach to tackling the human immunodeficiency virus (HIV) that causes AIDS, one it said could drastically cut the number of AIDS-related deaths and help to stop HIV from spreading. Get the full story »
FDA approves Abbott HIV test
Abbott Labs said the FDA today approved its new diagnostic test that allows for earlier detection of HIV. Get the full story »
